文献速递冠心病外科

多支动脉移植物改善多支病变冠状动脉血运重建患者早期主要不良心脑血管事件发生率:12615例分析

Multiarterial grafts improve the rate of early major adverse cardiac and cerebrovascular events in patients undergoing coronary revascularization: analysis of 12 615 patients with multivessel disease.
PubMed 文献 · Eur J Cardiothorac Surg · 2017-01-01

该研究比较了多支动脉(MultArt)CABG、左乳内动脉/大隐静脉(LIMA/SV)CABG与PCI在多支病变患者中早期(院内及30天)主要不良心脑血管事件(MACCE)的发生率。结果显示MultArt的早期MACCE最低(1.5%),优于LIMA/SV(4.5%)和PCI(8.5%),多因素分析中PCI和LIMA/SV是早期MACCE的强预测因子。

要点

  • MultArt的早期MACCE最低(1.5%),优于LIMA/SV(4.5%)和PCI(8.5%)。
  • 匹配分析中MultArt vs PCI的早期MACCE为1.8% vs 7.8%(P<0.001)。
  • 多因素分析中PCI(OR 4.53)和LIMA/SV(OR 2.04)是早期MACCE的强预测因子。

核心结论

  • 多支动脉移植物(MultArt)的早期MACCE发生率最低。

主要发现

  • 未调整的早期MACCE:MultArt 1.5%,LIMA/SV 4.5%(P<0.001),PCI 8.5%(P<0.001)。
  • 匹配分析中CABG vs 球囊血管成形术的早期MACCE为4.7% vs 13.2%(P<0.001)。
  • 匹配分析中CABG vs 裸金属支架的早期MACCE为4.3% vs 8.3%(P<0.001)。
  • 匹配分析中CABG vs 药物洗脱支架的早期MACCE为2.9% vs 5.5%(P=0.008)。
  • 匹配分析中LIMA/SV vs PCI的早期MACCE为4.6% vs 9.2%(P<0.001),MultArt vs PCI为1.8% vs 7.8%(P<0.001)。

关键数值与推荐

  • MultArt vs PCI的卒中发生率相似(0.8% vs 0.3%,P=0.18),但LIMA/SV vs PCI的卒中发生率更高(2.3% vs 0.4%,P<0.001)。
  • 多因素分析中,PCI(OR 4.53,95%CI 2.62-7.83,P<0.001)和LIMA/SV(OR 2.04,95%CI 1.18-3.53,P<0.011)是早期MACCE的强预测因子(参照MultArt)。

临床怎么用

  • 对于多支病变血运重建患者,多支动脉CABG策略可能降低早期MACCE风险。

局限性

  • 研究为回顾性设计,早期MACCE定义包含重复血运重建,结果需结合现代技术和患者选择解读。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Our goal was to compare the rates of in-hospital and 30-day major adverse cardiac and cerebrovascular events (MACCE) including death, stroke, myocardial infarction and repeat revascularization in patients with multivessel disease undergoing multiarterial (MultArt) coronary artery bypass grafting (CABG) with the left internal mammary artery/saphenous vein (LIMA/SV) CABG or percutaneous coronary intervention (PCI). METHODS: From 1 January 1993 to 31 December 2009, 12 615 consecutive patients underwent isolated primary CABG (n = 6667) with LIMA/SV (n = 5712) or MultArt (n = 955) or were treated by PCI (n = 5948) with balloon angioplasty (n = 1020), bare metal stent (n = 3242), and drug-eluting stent (n = 1686). We excluded patients with acute myocardial infarction. We matched the CABG group with the 3 PCI subgroups, and the PCI group with the 2 CABG subgroups. Multivariable analyses were used to evaluate the impact of CABG versus PCI and their subgroups on early MACCE. RESULTS: Unadjusted early MACCE were lower for MultArt (1.5%) than for LIMA/SV (4.5%, P < 0.001) and PCI (8.5%, P < 0.001). In matched analysis, CABG had lower early MACCE versus balloon angioplasty (4.7% vs 13.2%, P < 0.001), bare metal stent (4.3% vs 8.3%, P < 0.001), and drug-eluting stent (2.9% vs 5.5%, P = 0.008), as well as LIMA/SV versus PCI (4.6% vs 9.2%, P < 0.001) and MultArt versus PCI (1.8% vs 7.8%, P < 0.001). Stroke rate was similar in MultArt versus PCI (0.8% vs 0.3%, P = 0.18) but higher with LIMA/SV versus PCI (2.3% vs 0.4%, P < 0.001). In multivariable analysis, PCI (odds ratio 4.53, 95% confidence interval: 2.62-7.83; P < 0.001) and LIMA/SV (odds ratio 2.04, 95% confidence interval: 1.18-3.53; P < 0.011) were strong predictors of early MACCE compared with MultArt. CONCLUSIONS: MultArt confers the lowest rate of early MACCE.

来源:Eur J Cardiothorac Surg,查看原文。版权归原作者所有。

引用

  1. Locker C, Schaff HV, Daly RC, et al. Multiarterial grafts improve the rate of early major adverse cardiac and cerebrovascular events in patients undergoing coronary revascularization: analysis of 12 615 patients with multivessel disease. Eur J Cardiothorac Surg. 2017. PMID: 28595326. doi:10.1093/ejcts/ezx171

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。